期刊文献+

SU11248干预白血病细胞K562对WWOX及相关基因表达的影响 被引量:1

Effect of SU11248 on the expression of WWOX and related protein in leukemia cell line K562
下载PDF
导出
摘要 目的:探讨SU11248对白血病细胞K562的作用及对K562表达WWOX和相关蛋白的影响。方法:以MTT法检测SU11248对K562细胞增殖能力的影响;RT-PCR检测SU11248干预K562细胞前后WWOX、BCL-2、BAX mRNA表达变化。Western blot检测SU11248处理K562细胞前后Wwox、Bcl-2蛋白的表达变化。结果:SU11248作用后K562细胞增殖受到明显抑制(P<0.05),呈现剂量和时间依赖性,半数抑制浓度(IC50)约为3.2μg/ml。3.2μg/ml SU11248作用后,K562细胞BCL-2 mRNA表达水平随时间延长而逐渐降低,WWOX mRNA逐渐增强,而BAX mRNA表达无明显变化。Western blot显示Bcl-2蛋白呈时间依赖性降低,而Wwox蛋白呈时间依赖性增强。WWOX与BCL-2成负相关(P<0.05)。结论:SU11248抑制K562细胞增殖及诱导其凋亡作用可能与上调WWOX、下调Bcl-2的表达有关。 Objective:To study the effect of SUl1248 on K562 cells and the change of WWOX and related protein in K562 cells treated with SUl1248. Methods: Effect of SUl1248 on proliferation of K562 cells was detected by MTT assay. Changes of WWOX, BCL-2, BAX mRNA expression were estimated by RT-PCR. Expression of Wwox, Bcl-2 protein in K562 cells were detected by Western blot analysis. Results: The proliferation of K562 cells could be inhibited by SUl1248 in doseand time-dependent manner ( P 〈 0.05 ). The concentration of 50% growth inhibition ( ICs0 ) of SU11248 for K562 cells was 3.2 μg/ml. After treating K562 cells with 3.2 μg/ml SU11248 at different time points, the expression of BCL-2 mRNA and protein was reduced significantly, and the ex- pression of WWOX mRNA and protein was increased significantly in a time-dependent manner ( P 〈 0.05 ), but the expression of BAX mRNA had no change. The expression of WWOX mRNA and protein were negatively correlated to the expression of BCL-2 mRNA and protein, (P 〈 0.05 ). Conclusion: SU11248 could inhibit the proliferation of K562 cells which may be related to down-regulation of BCL-2 and up-regulation of WWOX.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2013年第4期366-369,381,共5页 Chinese Journal of Immunology
基金 福建省自然科学基金项目(2010J01181) 福建省医科大学教授基金资助项目(JS08009)
关键词 SU11248 K562细胞 WWOX 分子机制 SU11248 K562 cell WWOX Molecule mechanism
  • 相关文献

参考文献3

二级参考文献61

  • 1苗丽君,王静.Akt与肿瘤的研究进展[J].国外医学(生理病理科学与临床分册),2004,24(5):406-409. 被引量:38
  • 2林东红,陈惠瑜,胡建达.白血病细胞周期蛋白G基因mRNA的表达及其临床意义[J].中国肿瘤生物治疗杂志,2006,13(5):376-380. 被引量:3
  • 3Gordon E,Liu P,Chen Z,et al.Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct[J].Cancer Res,2000,60(13):3343-3347.
  • 4Endo Y,Fujita T,Tamura K,et al.Structure and chromosomal assignment of the human cyclin G gene[J].Genomics,1996,38(1):92-95.
  • 5Jung CW,Kim ES,Seol JG,et al.Antiproliferative effect of a vitamin D3 analog,EB1089,on HL-60 cells by the induction of TGF-beta receptor[J].Leuk Res,1999,23(12):1105-1112.
  • 6Jonuleit T,Van-der-kuip H,Miething C,et al.Bcr-abl kinase down-regulation cyclin-dependent kinase inhibitor p27 in human and murine cell lines[J].Blood,2002,96(5):1933-1939.
  • 7Yokozawa T,Yowatari M,Lida H,et al.Prognostic significance of the cell cycle inhibitor p27 Kip1 in acute myeloid leukemia[J].Leukemia,2000,14(1):28-31.
  • 8Rock EP,Goodman V,Jiang JX,et al.Food and drug adminstration drug approval summary:Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma[J].Oncologist,2007,12(1):107-113.
  • 9Motzer RJ,Michaelson MD,Redman BG,et al.Activity of SU 11248,a multitargeted inhibitor of vascular endothelial growth factor receptor and platetel-derived growth factor receptor,in patients with metastatic renal cell carcinoma[J].J CIin Oncol,2006,24(1):16-24.
  • 10Fiedler W,Serve H,Dohner H,et al.A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease[J].Blood,2005,105(3):986-993.

共引文献9

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部